Close Menu

GE Healthcare

The cancer genetics testing provider acquired its new business unit from GE Healthcare.

By buying Clarient, NeoGenomics hopes to move closer to its goal of becoming America's top cancer genetic testing lab.

NeoGenomics and GE Healthcare will also collaborate on a bioinformatics initiative for personalized oncology.

The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.

The licenses provide non-exclusive access to the IP for research applications.

General Electric has been awarded

NEW YORK (GenomeWeb) – GE Healthcare today announced a deal between its affiliate Clarient Diagnostic Services and GlaxoSmithKline to create a network of clinical laboratories to identify genetic mutations associated with different tumor types.

Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013

GE Healthcare this week launched the illustra Single Cell GenomiPhi DNA amplification kit from.

Pages

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.